Carl Icahn (Heidi Gutman/CNBC/NBCU Photo Bank/NBCUniversal via Getty Images)
March 13, 2023 07:19 AM EDTUpdated 02:16 PM
People
Startups

Up­dat­ed: Carl Ic­ahn pro­pos­es three new Il­lu­mi­na board mem­bers in proxy fight

Kyle LaHucik

Senior Reporter

A proxy fight is brew­ing at Il­lu­mi­na as ac­tivist in­vestor Carl Ic­ahn ar­gues that the DNA se­quenc­ing gi­ant is cost­ing share­hold­ers bil­lions by fol­low­ing through …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times